APO Research
Talk to an analyst

APO RESEARCH · REPORT

Macromolecular Single-target Angiogenesis Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Macromolecular Single-target Angiogenesis Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025190 pages

Choose your research edition.

Industry ResearchMacromolecular Single-target Angiogenesis Inhibitor Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Macromolecular Single-target Angiogenesis Inhibitor Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Macromolecular Single-target Angiogenesis Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Macromolecular Single-target Angiogenesis Inhibitor Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Macromolecular Single-target Angiogenesis Inhibitor Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Macromolecular Single-target Angiogenesis Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Macromolecular Single-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Macromolecular Single-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Macromolecular Single-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Macromolecular Single-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Macromolecular Single-target Angiogenesis Inhibitor include Amgen, Amneal Pharmaceuticals, Bayer, Celltrion Healthcare, Eli Lilly, Pfizer, Roche, Sanofi and Jiangsu Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Macromolecular Single-target Angiogenesis Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Macromolecular Single-target Angiogenesis Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Macromolecular Single-target Angiogenesis Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Macromolecular Single-target Angiogenesis Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

Macromolecular Single-target Angiogenesis Inhibitor Segment by Company

Amgen

Amneal Pharmaceuticals

Bayer

Celltrion Healthcare

Eli Lilly

Pfizer

Roche

Sanofi

Jiangsu Hengrui Pharmaceuticals

Qilu Pharma

SinoCellTech

Innovent

Chia Tai Tianqing

Macromolecular Single-target Angiogenesis Inhibitor Segment by Type

Aflibercept

Bevacizumab

Ramucirumab

Other

Macromolecular Single-target Angiogenesis Inhibitor Segment by Application

Degenerative Eye Diseases

Cancer

Other

Macromolecular Single-target Angiogenesis Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Macromolecular Single-target Angiogenesis Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Macromolecular Single-target Angiogenesis Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Macromolecular Single-target Angiogenesis Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Macromolecular Single-target Angiogenesis Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Macromolecular Single-target Angiogenesis Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Macromolecular Single-target Angiogenesis Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Macromolecular Single-target Angiogenesis Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Macromolecular Single-target Angiogenesis Inhibitor Industry Trends Table 2. Macromolecular Single-target Angiogenesis Inhibitor Industry Drivers Table 3. Macromolecular Single-target Angiogenesis Inhibitor Industry Opportunities and Challenges Table 4. Macromolecular Single-target Angiogenesis Inhibitor Industry Restraints Table 5. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Manufacturers Table 9. Global Macromolecular Single-target Angiogenesis Inhibitor Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Macromolecular Single-target Angiogenesis Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Macromolecular Single-target Angiogenesis Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Macromolecular Single-target Angiogenesis Inhibitor Manufacturers, Product Type & Application Table 13. Global Macromolecular Single-target Angiogenesis Inhibitor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Macromolecular Single-target Angiogenesis Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Aflibercept Table 17. Major Manufacturers of Bevacizumab Table 18. Major Manufacturers of Ramucirumab Table 19. Major Manufacturers of Other Table 20. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (K Units) Table 22. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type (2027-2032) & (K Units) Table 23. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2026) Table 24. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Type (2027-2032) Table 25. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Type (2021-2026) & (K Units) Table 27. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Type (2027-2032) & (K Units) Table 28. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Type (2021-2026) Table 29. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Degenerative Eye Diseases Table 31. Major Manufacturers of Cancer Table 32. Major Manufacturers of Other Table 33. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (K Units) Table 35. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application (2027-2032) & (K Units) Table 36. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Application (2021-2026) Table 37. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Application (2027-2032) Table 38. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Application (2021-2026) & (K Units) Table 40. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Application (2027-2032) & (K Units) Table 41. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Application (2021-2026) Table 42. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Application (2027-2032) Table 43. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region (2021-2026) & (K Units) Table 45. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Region (2021-2026) Table 46. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Macromolecular Single-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 50. North America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2027-2032) & (K Units) Table 51. Europe Macromolecular Single-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 53. Europe Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2027-2032) & (K Units) Table 60. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Region (2021-2026) Table 64. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Region (2027-2032) Table 65. Amgen Company Information Table 66. Amgen Business Overview Table 67. Amgen Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Amgen Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 69. Amgen Recent Development Table 70. Amneal Pharmaceuticals Company Information Table 71. Amneal Pharmaceuticals Business Overview Table 72. Amneal Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Amneal Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 74. Amneal Pharmaceuticals Recent Development Table 75. Bayer Company Information Table 76. Bayer Business Overview Table 77. Bayer Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Bayer Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 79. Bayer Recent Development Table 80. Celltrion Healthcare Company Information Table 81. Celltrion Healthcare Business Overview Table 82. Celltrion Healthcare Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Celltrion Healthcare Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 84. Celltrion Healthcare Recent Development Table 85. Eli Lilly Company Information Table 86. Eli Lilly Business Overview Table 87. Eli Lilly Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Eli Lilly Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 89. Eli Lilly Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Pfizer Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 94. Pfizer Recent Development Table 95. Roche Company Information Table 96. Roche Business Overview Table 97. Roche Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Roche Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 99. Roche Recent Development Table 100. Sanofi Company Information Table 101. Sanofi Business Overview Table 102. Sanofi Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Sanofi Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 104. Sanofi Recent Development Table 105. Jiangsu Hengrui Pharmaceuticals Company Information Table 106. Jiangsu Hengrui Pharmaceuticals Business Overview Table 107. Jiangsu Hengrui Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Jiangsu Hengrui Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 109. Jiangsu Hengrui Pharmaceuticals Recent Development Table 110. Qilu Pharma Company Information Table 111. Qilu Pharma Business Overview Table 112. Qilu Pharma Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Qilu Pharma Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 114. Qilu Pharma Recent Development Table 115. SinoCellTech Company Information Table 116. SinoCellTech Business Overview Table 117. SinoCellTech Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. SinoCellTech Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 119. SinoCellTech Recent Development Table 120. Innovent Company Information Table 121. Innovent Business Overview Table 122. Innovent Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Innovent Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 124. Innovent Recent Development Table 125. Chia Tai Tianqing Company Information Table 126. Chia Tai Tianqing Business Overview Table 127. Chia Tai Tianqing Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Chia Tai Tianqing Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio Table 129. Chia Tai Tianqing Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Macromolecular Single-target Angiogenesis Inhibitor Distributors List Table 133. Macromolecular Single-target Angiogenesis Inhibitor Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Macromolecular Single-target Angiogenesis Inhibitor Product Image Figure 2. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global Macromolecular Single-target Angiogenesis Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global Macromolecular Single-target Angiogenesis Inhibitor Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Macromolecular Single-target Angiogenesis Inhibitor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Aflibercept Image Figure 9. Bevacizumab Image Figure 10. Ramucirumab Image Figure 11. Other Image Figure 12. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2032) Figure 15. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Type (2021-2032) Figure 18. Degenerative Eye Diseases Image Figure 19. Cancer Image Figure 20. Other Image Figure 21. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Application (2021-2032) Figure 24. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Application (2021-2032) Figure 27. North America Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2032) Figure 29. U.S. Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2032) Figure 34. Germany Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2032) Figure 41. China Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2032) Figure 49. Brazil Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Macromolecular Single-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Macromolecular Single-target Angiogenesis Inhibitor Revenue (2021-2032) & (US$ Million) Figure 60. North America Macromolecular Single-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Macromolecular Single-target Angiogenesis Inhibitor Revenue (2021-2032) & (US$ Million) Figure 62. Europe Macromolecular Single-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Macromolecular Single-target Angiogenesis Inhibitor Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Macromolecular Single-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Macromolecular Single-target Angiogenesis Inhibitor Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Macromolecular Single-target Angiogenesis Inhibitor Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Aflibercept
  • Bevacizumab
  • Ramucirumab
  • Other
Applications
  • Degenerative Eye Diseases
  • Cancer
  • Other
Companies covered
  • Amgen
  • Amneal Pharmaceuticals
  • Bayer
  • Celltrion Healthcare
  • Eli Lilly
  • Pfizer
  • Roche
  • Sanofi
  • Jiangsu Hengrui Pharmaceuticals
  • Qilu Pharma
  • SinoCellTech
  • Innovent
  • Chia Tai Tianqing

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Macromolecular Single-target Angiogenesis Inhibitor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Macromolecular Single-target Angiogenesis Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Macromolecular Single-target Angiogenesis Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Macromolecular Single-target Angiogenesis Inhibitor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Macromolecular Single-target Angiogenesis Inhibitor Market Dynamics
  1. 2.1 Macromolecular Single-target Angiogenesis Inhibitor Industry Trends
  2. 2.2 Macromolecular Single-target Angiogenesis Inhibitor Industry Drivers
  3. 2.3 Macromolecular Single-target Angiogenesis Inhibitor Industry Opportunities and Challenges
  4. 2.4 Macromolecular Single-target Angiogenesis Inhibitor Industry Restraints
3 Macromolecular Single-target Angiogenesis Inhibitor Market by Manufacturers
  1. 3.1 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Manufacturers (2021-2026)
  3. 3.3 Global Macromolecular Single-target Angiogenesis Inhibitor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Macromolecular Single-target Angiogenesis Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Macromolecular Single-target Angiogenesis Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Macromolecular Single-target Angiogenesis Inhibitor Manufacturers, Product Type & Application
  7. 3.7 Global Macromolecular Single-target Angiogenesis Inhibitor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Macromolecular Single-target Angiogenesis Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Macromolecular Single-target Angiogenesis Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Macromolecular Single-target Angiogenesis Inhibitor Tier 1, Tier 2, and Tier 3
4 Macromolecular Single-target Angiogenesis Inhibitor Market by Type
  1. 4.1 Macromolecular Single-target Angiogenesis Inhibitor Type Introduction
  2. 4.1.1 Aflibercept
  3. 4.1.2 Bevacizumab
  4. 4.1.3 Ramucirumab
  5. 4.1.4 Other
  6. 4.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type
  7. 4.2.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type (2021-2032)
  9. 4.2.3 Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2032)
  10. 4.3 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Type
  11. 4.3.1 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Type (2021-2032)
  13. 4.3.3 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Type (2021-2032)
5 Macromolecular Single-target Angiogenesis Inhibitor Market by Application
  1. 5.1 Macromolecular Single-target Angiogenesis Inhibitor Application Introduction
  2. 5.1.1 Degenerative Eye Diseases
  3. 5.1.2 Cancer
  4. 5.1.3 Other
  5. 5.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application
  6. 5.2.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application (2021-2032)
  8. 5.2.3 Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Application (2021-2032)
  9. 5.3 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Application
  10. 5.3.1 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Application (2021-2032)
  12. 5.3.3 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Application (2021-2032)
6 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region
  1. 6.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region (2021-2026)
  4. 6.2.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Macromolecular Single-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Macromolecular Single-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region
  1. 7.1 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region
  2. 7.1.1 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region (2021-2026)
  4. 7.1.3 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region (2027-2032)
  5. 7.1.4 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Macromolecular Single-target Angiogenesis Inhibitor Revenue (2021-2032)
  8. 7.2.2 North America Macromolecular Single-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Macromolecular Single-target Angiogenesis Inhibitor Revenue (2021-2032)
  11. 7.3.2 Europe Macromolecular Single-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Macromolecular Single-target Angiogenesis Inhibitor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Macromolecular Single-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen Macromolecular Single-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Amneal Pharmaceuticals
  8. 8.2.1 Amneal Pharmaceuticals Company Information
  9. 8.2.2 Amneal Pharmaceuticals Business Overview
  10. 8.2.3 Amneal Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amneal Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  12. 8.2.5 Amneal Pharmaceuticals Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Macromolecular Single-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 Celltrion Healthcare
  20. 8.4.1 Celltrion Healthcare Company Information
  21. 8.4.2 Celltrion Healthcare Business Overview
  22. 8.4.3 Celltrion Healthcare Macromolecular Single-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Celltrion Healthcare Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  24. 8.4.5 Celltrion Healthcare Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Macromolecular Single-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Macromolecular Single-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Macromolecular Single-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Macromolecular Single-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
  49. 8.9 Jiangsu Hengrui Pharmaceuticals
  50. 8.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
  51. 8.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  52. 8.9.3 Jiangsu Hengrui Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Hengrui Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  54. 8.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  55. 8.10 Qilu Pharma
  56. 8.10.1 Qilu Pharma Company Information
  57. 8.10.2 Qilu Pharma Business Overview
  58. 8.10.3 Qilu Pharma Macromolecular Single-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Qilu Pharma Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  60. 8.10.5 Qilu Pharma Recent Developments
  61. 8.11 SinoCellTech
  62. 8.11.1 SinoCellTech Company Information
  63. 8.11.2 SinoCellTech Business Overview
  64. 8.11.3 SinoCellTech Macromolecular Single-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 SinoCellTech Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  66. 8.11.5 SinoCellTech Recent Developments
  67. 8.12 Innovent
  68. 8.12.1 Innovent Company Information
  69. 8.12.2 Innovent Business Overview
  70. 8.12.3 Innovent Macromolecular Single-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Innovent Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  72. 8.12.5 Innovent Recent Developments
  73. 8.13 Chia Tai Tianqing
  74. 8.13.1 Chia Tai Tianqing Company Information
  75. 8.13.2 Chia Tai Tianqing Business Overview
  76. 8.13.3 Chia Tai Tianqing Macromolecular Single-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Chia Tai Tianqing Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio
  78. 8.13.5 Chia Tai Tianqing Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Macromolecular Single-target Angiogenesis Inhibitor Value Chain Analysis
  2. 9.1.1 Macromolecular Single-target Angiogenesis Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Macromolecular Single-target Angiogenesis Inhibitor Production Mode & Process
  6. 9.2 Macromolecular Single-target Angiogenesis Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Macromolecular Single-target Angiogenesis Inhibitor Distributors
  9. 9.2.3 Macromolecular Single-target Angiogenesis Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst